Last 12 months
Inside the activity.
0 purchase rows · 12 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2023 Filed Aug 7, 2023 20:35 UTC |
HOLLAND CHRISTOPHER SDirector
|
GrantCareer Restricted Stock Units · Derivative | 525 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-044822 · doc4.xml · derivative · entry 2 HOLLAND CHRISTOPHER S · CIK 0001271440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,989 Underlying: Ordinary Shares · 525 shares Expires not disclosed F2 · derivative.exercise_price: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. F3 · derivative.exercise_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. F3 · derivative.expiration_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 20:35 UTC |
HOLLAND CHRISTOPHER SDirector
|
GrantDirector Stock Option (right to buy) · Derivative | 1,544 | $0.00 Strike: $225.50 | $0.00 |
DisclosureSEC source: 0001209191-23-044822 · doc4.xml · derivative · entry 1 HOLLAND CHRISTOPHER S · CIK 0001271440 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,544 Underlying: Ordinary Shares · 1,544 shares Expires 2033-08-03 F1 · derivative.exercise_date: These nonqualified stock options are fully vested and are exercisable immediately. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 16:30 UTC |
Xilas AndrewSVP and GM, Dental
|
Tax withholdingOrdinary Shares | 103 | $205.47 | $21,163.41 |
DisclosureSEC source: 0001209191-23-034766 · doc4.xml · nonDerivative · entry 1 Xilas Andrew · CIK 0001863490 · SVP and GM, Dental 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,894 F1 · shares: 103 shares were withheld from the 352 restricted shares that vested on June 2, 2023. These 103 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 352 ordinary shares were awarded to Mr. Xilas on June 2, 2022. These vested shares were valued at the NYSE closing market price on June 2, 2023. F2 · balance_after: As of June 2, 2023, 3,201 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 289 on October 2, 2023; 426 on May 31, 2024, 352 on June 3, 2024; 289 on October 1, 2024; 426 on June 2, 2025, 352 on June 2, 2025; 289 on October 1, 2025, 426 on June 1, 2026 and 352 on June 2, 2026. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:30 UTC |
Madsen JuliaSenior VP, Life Sciences
|
Tax withholdingOrdinary Shares | 247 | $205.47 | $50,751.09 |
DisclosureSEC source: 0001209191-23-034762 · doc4.xml · nonDerivative · entry 1 Madsen Julia · CIK 0001819129 · Senior VP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,722 F1 · shares: 247 shares were withheld from the 712 restricted shares that vested on June 2, 2023. These 247 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 712 ordinary shares were awarded to Ms. Madsen on June 2, 2021 and June 2, 2022. These vested shares were valued at the NYSE closing market price on June 2, 2023. F2 · balance_after: As of June 2, 2023, 4,763 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 349 on October 2, 2023; 144 on October 2, 2023; 578 on May 31, 2024; 352 on June 3, 2024; 123 on June 3, 2024; 360 on June 3, 2024; 349 on October 1, 2024; 144 on October 1, 2024; 578 on June 2, 2025; 352 on June 2, 2025; 360 on June 2, 2025; 144 on October 1, 2025; 578 on June 1, 2026 and 352 on June 2, 2026. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:30 UTC |
Burton Karen LVP, Controller & CAO
|
Tax withholdingOrdinary Shares | 127 | $205.47 | $26,094.69 |
DisclosureSEC source: 0001209191-23-034765 · doc4.xml · nonDerivative · entry 1 Burton Karen L · CIK 0001697095 · VP, Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,785 F1 · shares: 127 shares were withheld from the 421 restricted shares that vested on June 2, 2023. These 127 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 421 ordinary shares were awarded to Ms. Burton on June 2, 2021 and June 2, 2022. These vested shares were valued at the NYSE closing market price on June 2, 2023. F2 · balance_after: As of June 2, 2023, 2,543 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 86 on October 2, 2023; 340 on May 31, 2024; 198 on June 3, 2024; 225 on June 3, 2024; 196 on June 3, 2024; 86 on October 1, 2024; 340 on June 2, 2025; 225 on June 2, 2025; 196 on June 2, 2025; 86 on October 1, 2025; 340 on June 1, 2026 and 225 on June 2, 2026. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:30 UTC |
Carestio Daniel ADirector · President and CEO
|
Tax withholdingOrdinary Shares | 2,422 | $205.47 | $497,648.34 |
DisclosureSEC source: 0001209191-23-034764 · doc4.xml · nonDerivative · entry 1 Carestio Daniel A · CIK 0001651806 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,106 F1 · shares: 2,422 shares were withheld from the 5,397 restricted shares that vested on June 2, 2023. These 2,422 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 5,397 ordinary shares were awarded to Mr. Carestio on June 2, 2021 and June 2, 2022. These vested shares were valued at the NYSE closing market price on June 2, 2023. F2 · balance_after: As of June 2, 2023, 25,034 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 289 on October 2, 2023; 4,308 on May 31, 2024; 1,108 on June 3, 2024; 2,369 on June 3, 2024; 1,514 on June 3, 2024; 289 on October 1, 2024; 4,308 on June 2, 2025; 1,514 on June 2, 2025; 2,369 on June 2, 2025; 289 on October 1, 2025; 4,308 on June 1, 2026 and 2,369 on June 2, 2026. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 20:30 UTC |
Zangerle John AdamSr. VP, Gen Counsel, and Sec.
|
Tax withholdingOrdinary Shares | 498 | $205.47 | $102,324.06 |
DisclosureSEC source: 0001209191-23-034763 · doc4.xml · nonDerivative · entry 1 Zangerle John Adam · CIK 0001578804 · Sr. VP, Gen Counsel, and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,344 F1 · shares: 498 shares were withheld from the 1,665 restricted shares that vested on June 2, 2023. These 498 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 1,665 ordinary shares were awarded to Mr. Zangerle on June 2, 2021 and June 2, 2022. These vested shares were valued at the NYSE closing market price on June 2, 2023. F2 · balance_after: As of June 2, 2023, 9,005 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 202 on October 2, 2023; 1,157 on May 31, 2024; 846 on June 3, 2024; 752 on June 3, 2024; 819 on June 3, 2024; 202 on October 1, 2024; 1,157 on June 2, 2025; 819 on June 2, 2025; 846 on June 2, 2025; 202 on October 1, 2025; 1,157 on June 1, 2026 and 846 on June 2, 2026. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:30 UTC |
Madsen JuliaSenior VP, Life Sciences
|
Tax withholdingOrdinary Shares | 43 | $202.42 | $8,704.06 |
DisclosureSEC source: 0001209191-23-034302 · doc4.xml · nonDerivative · entry 1 Madsen Julia · CIK 0001819129 · Senior VP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,969 F1 · shares: 43 shares were withheld from the 123 restricted shares that vested on June 1, 2023. These 43 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 123 ordinary shares were awarded to Ms. Madsen on June 1, 2020. These vested shares were valued at the NYSE closing market price on June 1, 2023. F2 · balance_after: As of June 1, 2023, 5,475 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 352 on June 2, 2023; 360 on June 2, 2023; 349 on October 2, 2023; 144 on October 2, 2023; 578 on May 31, 2024; 352 on June 3, 2024; 123 on June 3, 2024; 360 on June 3, 2024; 349 on October 1, 2024; 144 on October 1, 2024; 578 on June 2, 2025; 352 on June 2, 2025; 360 on June 2, 2025; 144 on October 1, 2025; 578 on June 1, 2026 and 352 on June 2, 2026. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:30 UTC |
Fraser Mary ClareSVP & Chief HRO
|
Tax withholdingOrdinary Shares | 236 | $202.42 | $47,771.12 |
DisclosureSEC source: 0001209191-23-034306 · doc4.xml · nonDerivative · entry 1 Fraser Mary Clare · CIK 0001818882 · SVP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,328 F1 · shares: 236 shares were withheld from the 791 restricted shares that vested on June 1, 2023. These 236 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 791 ordinary shares were awarded to Ms. Fraser on August 4, 2020. These vested shares were valued at the NYSE closing market price on June 1, 2023. F2 · balance_after: As of June 1, 2023, 7,660 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 791 on June 1, 2024; 1,836 on June 2, 2025; 692 on October 1, 2025; 2,313 on June 1, 2026 and 2,028 on June 2, 2026. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:30 UTC |
Zangerle John AdamSr. VP, Gen Counsel, and Sec.
|
Tax withholdingOrdinary Shares | 225 | $202.42 | $45,544.50 |
DisclosureSEC source: 0001209191-23-034305 · doc4.xml · nonDerivative · entry 1 Zangerle John Adam · CIK 0001578804 · Sr. VP, Gen Counsel, and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,842 F1 · shares: 225 shares were withheld from the 752 restricted shares that vested on June 1, 2023. These 225 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 752 ordinary shares were awarded to Mr. Zangerle on June 1, 2020. These vested shares were valued at the NYSE closing market price on June 1, 2023. F2 · balance_after: As of June 1, 2023, 10,670 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 846 on June 2, 2023; 819 on June 2, 2023; 202 on October 2, 2023; 1,157 on May 31, 2024; 846 on June 3, 2024; 752 on June 3, 2024; 819 on June 3, 2024; 202 on October 1, 2024; 1,157 on June 2, 2025; 819 on June 2, 2025; 846 on June 2, 2025; 202 on October 1, 2025; 1,157 on June 1, 2026 and 846 on June 2, 2026. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:30 UTC |
Burton Karen LVP, Controller & CAO
|
Tax withholdingOrdinary Shares | 60 | $202.42 | $12,145.20 |
DisclosureSEC source: 0001209191-23-034303 · doc4.xml · nonDerivative · entry 1 Burton Karen L · CIK 0001697095 · VP, Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,912 F1 · shares: 60 shares were withheld from the 198 restricted shares that vested on June 1, 2023. These 60 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 198 ordinary shares were awarded to Ms. Burton on June 1, 2020. These vested shares were valued at the NYSE closing market price on June 1, 2023. F2 · balance_after: As of June 1, 2023, 2,964 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 225 on June 2, 2023; 196 on June 2, 2023; 86 on October 2, 2023; 340 on May 31, 2024; 198 on June 3, 2024; 225 on June 3, 2024; 196 on June 3, 2024; 86 on October 1, 2024; 340 on June 2, 2025; 225 on June 2, 2025; 196 on June 2, 2025; 86 on October 1, 2025; 340 on June 1, 2026 and 225 on June 2, 2026. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:30 UTC |
Carestio Daniel ADirector · President and CEO
|
Tax withholdingOrdinary Shares | 1,491 | $202.42 | $301,808.22 |
DisclosureSEC source: 0001209191-23-034307 · doc4.xml · nonDerivative · entry 1 Carestio Daniel A · CIK 0001651806 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,528 F1 · shares: 1,491 shares were withheld from the 3,324 restricted shares that vested on June 1, 2023. These 1,491 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 3,324 ordinary shares were awarded to Mr. Carestio on June 1, 2020. These vested shares were valued at the NYSE closing market price on June 1, 2023. F2 · balance_after: As of June 1, 2023, 30,431 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 3,028 on June 2, 2023; 2,369 on June 2, 2023; 289 on October 2, 2023; 4,308 on May 31, 2024; 1,108 on June 3, 2024; 2,369 on June 3, 2024; 1,514 on June 3, 2024; 289 on October 1, 2024; 4,308 on June 2, 2025; 1,514 on June 2, 2025; 2,369 on June 2, 2025; 289 on October 1, 2025; 4,308 on June 1, 2026 and 2,369 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 16:30 UTC |
Xilas AndrewSVP and GM, Dental
|
GrantEmployee Stock Option (right to buy) · Derivative | 7,172 | $0.00 Strike: $219.97 | $0.00 |
DisclosureSEC source: 0001209191-23-033766 · doc4.xml · derivative · entry 2 Xilas Andrew · CIK 0001863490 · SVP and GM, Dental 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,172 Underlying: Ordinary Shares · 7,172 shares Expires 2033-05-31 F2 · derivative.exercise_date: This option becomes exercisable as follows: 1,793 on May 31, 2024; 1,793 on June 2, 2025; 1,793 on June 1, 2026 and 1,793 on June 1, 2027. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 16:30 UTC |
Xilas AndrewSVP and GM, Dental
|
GrantOrdinary Shares | 1,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033766 · doc4.xml · nonDerivative · entry 1 Xilas Andrew · CIK 0001863490 · SVP and GM, Dental 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,997 F1 · balance_after: As of May 31, 2023, 3,553 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 352 on June 2, 2023; 289 on October 2, 2023; 426 on May 31, 2024, 352 on June 3, 2024; 289 on October 1, 2024; 426 on June 2, 2025, 352 on June 2, 2025; 289 on October 1, 2025, 426 on June 1, 2026 and 352 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Madsen JuliaSenior VP, Life Sciences
|
GrantEmployee Stock Options (right to buy) · Derivative | 9,740 | $0.00 Strike: $219.97 | $0.00 |
DisclosureSEC source: 0001209191-23-033770 · doc4.xml · derivative · entry 3 Madsen Julia · CIK 0001819129 · Senior VP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,740 Underlying: Ordinary Shares · 9,740 shares Expires 2033-05-31 F3 · derivative.exercise_date: This option becomes exercisable as follows: 2,435 on May 31, 2024; 2,435 on June 2, 2025; 2,435 on June 1, 2026 and 2,435 on June 1, 2027. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Madsen JuliaSenior VP, Life Sciences
|
GrantOrdinary Shares | 1,734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033770 · doc4.xml · nonDerivative · entry 2 Madsen Julia · CIK 0001819129 · Senior VP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,012 F2 · balance_after: As of May 31, 2023, 5,598 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 123 on June 1, 2023; 352 on June 2, 2023; 360 on June 2, 2023; 349 on October 2, 2023; 144 on October 2, 2023; 578 on May 31, 2024; 352 on June 3, 2024; 123 on June 3, 2024; 360 on June 3, 2024; 349 on October 1, 2024; 144 on October 1, 2024; 578 on June 2, 2025; 352 on June 2, 2025; 360 on June 2, 2025; 144 on October 1, 2025; 578 on June 1, 2026 and 352 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Madsen JuliaSenior VP, Life Sciences
|
Tax withholdingOrdinary Shares | 32 | $199.97 | $6,399.04 |
DisclosureSEC source: 0001209191-23-033770 · doc4.xml · nonDerivative · entry 1 Madsen Julia · CIK 0001819129 · Senior VP, Life Sciences 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,278 F1 · shares: 32 shares were withheld from the 92 restricted shares that vested on May 31, 2023. These 32 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 92 ordinary shares were awarded to Ms. Madsen on May 31, 2019. These vested shares were valued at the NYSE closing market price on May 31, 2023. F2 · balance_after: As of May 31, 2023, 5,598 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 123 on June 1, 2023; 352 on June 2, 2023; 360 on June 2, 2023; 349 on October 2, 2023; 144 on October 2, 2023; 578 on May 31, 2024; 352 on June 3, 2024; 123 on June 3, 2024; 360 on June 3, 2024; 349 on October 1, 2024; 144 on October 1, 2024; 578 on June 2, 2025; 352 on June 2, 2025; 360 on June 2, 2025; 144 on October 1, 2025; 578 on June 1, 2026 and 352 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Fraser Mary ClareSVP & Chief HRO
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,984 | $0.00 Strike: $219.97 | $0.00 |
DisclosureSEC source: 0001209191-23-033773 · doc4.xml · derivative · entry 2 Fraser Mary Clare · CIK 0001818882 · SVP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,984 Underlying: Ordinary Shares · 12,984 shares Expires 2033-05-31 F2 · derivative.exercise_date: This option becomes exercisable as follows: 3,246 on May 31, 2024; 3,246 on June 2, 2025; 3,246 on June 1, 2026 and 3,246 on June 1, 2027. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Fraser Mary ClareSVP & Chief HRO
|
GrantOrdinary Shares | 2,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033773 · doc4.xml · nonDerivative · entry 1 Fraser Mary Clare · CIK 0001818882 · SVP & Chief HRO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,564 F1 · balance_after: As of May 31, 2023, 8,451 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 791 on June 1, 2023; 791 on June 1, 2024; 1,836 on June 2, 2025; 692 on October 1, 2025; 2,313 on June 1, 2026 and 2,028 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Burton Karen LVP, Controller & CAO
|
GrantEmployee Stock Options (right to buy) · Derivative | 3,820 | $0.00 Strike: $219.97 | $0.00 |
DisclosureSEC source: 0001209191-23-033777 · doc4.xml · derivative · entry 3 Burton Karen L · CIK 0001697095 · VP, Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,820 Underlying: Ordinary Shares · 3,820 shares Expires 2033-05-31 F3 · derivative.exercise_date: This option becomes exercisable as follows: 955 on May 31, 2024; 955 on June 2, 2025; 955 on June 1, 2026 and 955 on June 1, 2027. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Burton Karen LVP, Controller & CAO
|
GrantOrdinary Shares | 1,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033777 · doc4.xml · nonDerivative · entry 2 Burton Karen L · CIK 0001697095 · VP, Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,972 F2 · balance_after: As of May 31, 2023, 3,162 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 198 on June 1, 2023; 225 on June 2, 2023; 196 on June 2, 2023; 86 on October 2, 2023; 340 on May 31, 2024; 198 on June 3, 2024; 225 on June 3, 2024; 196 on June 3, 2024; 86 on October 1, 2024; 340 on June 2, 2025; 225 on June 2, 2025; 196 on June 2, 2025; 86 on October 1, 2025; 340 on June 1, 2026 and 225 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Burton Karen LVP, Controller & CAO
|
Tax withholdingOrdinary Shares | 76 | $199.97 | $15,197.72 |
DisclosureSEC source: 0001209191-23-033777 · doc4.xml · nonDerivative · entry 1 Burton Karen L · CIK 0001697095 · VP, Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,952 F1 · shares: 76 shares were withheld from the 255 restricted shares that vested on May 31, 2023. These 76 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 255 ordinary shares were awarded to Ms. Burton on May 31, 2019. These vested shares were valued at the NYSE closing market price on May 31, 2023. F2 · balance_after: As of May 31, 2023, 3,162 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 198 on June 1, 2023; 225 on June 2, 2023; 196 on June 2, 2023; 86 on October 2, 2023; 340 on May 31, 2024; 198 on June 3, 2024; 225 on June 3, 2024; 196 on June 3, 2024; 86 on October 1, 2024; 340 on June 2, 2025; 225 on June 2, 2025; 196 on June 2, 2025; 86 on October 1, 2025; 340 on June 1, 2026 and 225 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Alegria Esther M.Director
|
GrantCareer Restricted Stock Units · Derivative | 371 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033768 · doc4.xml · derivative · entry 1 Alegria Esther M. · CIK 0001867056 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 371 Underlying: Ordinary Shares · 371 shares Expires not disclosed F1 · derivative.exercise_price: Each Career Restricted Stock Unit represents the right to receive one STERIS ordinary share six months after the cessation of the Director's Board service. F2 · derivative.exercise_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. F2 · derivative.expiration_date: These Career Restricted Stock Units are fully vested immediately. They will be settled in STERIS ordinary shares six months after the cessation of the Director's Board service. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Zangerle John AdamSr. VP, Gen Counsel, and Sec.
|
GrantEmployee Stock Option (right to buy) · Derivative | 19,480 | $0.00 Strike: $219.97 | $0.00 |
DisclosureSEC source: 0001209191-23-033772 · doc4.xml · derivative · entry 3 Zangerle John Adam · CIK 0001578804 · Sr. VP, Gen Counsel, and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,480 Underlying: Ordinary Shares · 19,480 shares Expires 2033-05-31 F3 · derivative.exercise_date: This option becomes exercisable as follows: 4,870 on May 31, 2024; 4,870 on June 2, 2025; 4,870 on June 1, 2026 and 4,870 on June 1, 2027. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Zangerle John AdamSr. VP, Gen Counsel, and Sec.
|
GrantOrdinary Shares | 3,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033772 · doc4.xml · nonDerivative · entry 2 Zangerle John Adam · CIK 0001578804 · Sr. VP, Gen Counsel, and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,067 F2 · balance_after: As of May 31, 2023, 11,422 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 752 on June 1, 2023; 846 on June 2, 2023; 819 on June 2, 2023; 202 on October 2, 2023; 1,157 on May 31, 2024; 846 on June 3, 2024; 752 on June 3, 2024; 819 on June 3, 2024; 202 on October 1, 2024; 1,157 on June 2, 2025; 819 on June 2, 2025; 846 on June 2, 2025; 202 on October 1, 2025; 1,157 on June 1, 2026 and 846 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC |
Zangerle John AdamSr. VP, Gen Counsel, and Sec.
|
Tax withholdingOrdinary Shares | 249 | $199.97 | $49,792.53 |
DisclosureSEC source: 0001209191-23-033772 · doc4.xml · nonDerivative · entry 1 Zangerle John Adam · CIK 0001578804 · Sr. VP, Gen Counsel, and Sec. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,596 F1 · shares: 249 shares were withheld from the 834 restricted shares that vested on May 31, 2023. These 249 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 834 ordinary shares were awarded to Mr. Zangerle on May 31, 2019. These vested shares were valued at the NYSE closing market price on May 31, 2023. F2 · balance_after: As of May 31, 2023, 11,422 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 752 on June 1, 2023; 846 on June 2, 2023; 819 on June 2, 2023; 202 on October 2, 2023; 1,157 on May 31, 2024; 846 on June 3, 2024; 752 on June 3, 2024; 819 on June 3, 2024; 202 on October 1, 2024; 1,157 on June 2, 2025; 819 on June 2, 2025; 846 on June 2, 2025; 202 on October 1, 2025; 1,157 on June 1, 2026 and 846 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
Tamaro RenatoV.P. & Corporate Treasurer
|
GrantEmployee Stock Option (right to buy) · Derivative | 2,704 | $0.00 Strike: $219.97 | $0.00 |
DisclosureSEC source: 0001209191-23-033765 · doc4.xml · derivative · entry 3 Tamaro Renato · CIK 0001713987 · V.P. & Corporate Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,704 Underlying: Ordinary Shares · 2,704 shares Expires 2033-05-31 F3 · derivative.exercise_date: This option becomes exercisable as follows: 676 on May 31, 2024; 676 on June 2, 2025; 676 on June 1, 2026 and 676 on June 1, 2027. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
Tamaro RenatoV.P. & Corporate Treasurer
|
GrantOrdinary Shares | 723 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033765 · doc4.xml · nonDerivative · entry 2 Tamaro Renato · CIK 0001713987 · V.P. & Corporate Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,677 F2 · balance_after: As of May 31, 2023, 2,791 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 241 on May 31, 2024; 584 on June 3, 2024; 282 on June 3, 2024; 432 on June 3, 2024; 258 on October 1, 2024; 241 on June 2, 2025; 144 on June 2, 2025; 141 on June 2, 2025; 86 on October 1, 2025; 241 on June 1, 2026 and 141 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
Tamaro RenatoV.P. & Corporate Treasurer
|
Tax withholdingOrdinary Shares | 175 | $199.97 | $34,994.75 |
DisclosureSEC source: 0001209191-23-033765 · doc4.xml · nonDerivative · entry 1 Tamaro Renato · CIK 0001713987 · V.P. & Corporate Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,954 F1 · shares: 175 shares were withheld from the 556 restricted shares that vested on May 31, 2023. These 175 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 556 ordinary shares were awarded to Mr. Tamaro on May 31, 2019. These vested shares were valued at the NYSE closing market price on May 31, 2023. F2 · balance_after: As of May 31, 2023, 2,791 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 241 on May 31, 2024; 584 on June 3, 2024; 282 on June 3, 2024; 432 on June 3, 2024; 258 on October 1, 2024; 241 on June 2, 2025; 144 on June 2, 2025; 141 on June 2, 2025; 86 on October 1, 2025; 241 on June 1, 2026 and 141 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
Carestio Daniel ADirector · President and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 89,808 | $0.00 Strike: $219.97 | $0.00 |
DisclosureSEC source: 0001209191-23-033761 · doc4.xml · derivative · entry 3 Carestio Daniel A · CIK 0001651806 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,808 Underlying: Ordinary Shares · 89,808 shares Expires 2033-05-31 F3 · derivative.exercise_date: This option becomes exercisable as follows: 22,452 on May 31, 2024; 22,452 on June 2, 2025; 22,452 on June 1, 2026 and 22,452 on June 1, 2027. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
Carestio Daniel ADirector · President and CEO
|
GrantOrdinary Shares | 12,924 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033761 · doc4.xml · nonDerivative · entry 2 Carestio Daniel A · CIK 0001651806 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,019 F2 · balance_after: As of May 31, 2023, 33,755 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 3,324 on June 1, 2023; 3,028 on June 2, 2023; 2,369 on June 2, 2023; 289 on October 2, 2023; 4,308 on May 31, 2024; 1,108 on June 3, 2024; 2,369 on June 3, 2024; 1,514 on June 3, 2024; 289 on October 1, 2024; 4,308 on June 2, 2025; 1,514 on June 2, 2025; 2,369 on June 2, 2025; 289 on October 1, 2025; 4,308 on June 1, 2026 and 2,369 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
Carestio Daniel ADirector · President and CEO
|
Tax withholdingOrdinary Shares | 1,506 | $199.97 | $301,154.82 |
DisclosureSEC source: 0001209191-23-033761 · doc4.xml · nonDerivative · entry 1 Carestio Daniel A · CIK 0001651806 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,095 F1 · shares: 1,506 shares were withheld from the 5,008 restricted shares that vested on May 31, 2023. These 1,506 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 5,008 ordinary shares were awarded to Mr. Carestio on May 31, 2019. These vested shares were valued at the NYSE closing market price on May 31, 2023. F2 · balance_after: As of May 31, 2023, 33,755 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 3,324 on June 1, 2023; 3,028 on June 2, 2023; 2,369 on June 2, 2023; 289 on October 2, 2023; 4,308 on May 31, 2024; 1,108 on June 3, 2024; 2,369 on June 3, 2024; 1,514 on June 3, 2024; 289 on October 1, 2024; 4,308 on June 2, 2025; 1,514 on June 2, 2025; 2,369 on June 2, 2025; 289 on October 1, 2025; 4,308 on June 1, 2026 and 2,369 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
Majors Cary LSVP and President, Healthcare
|
GrantEmployee Stock Option (right to buy) · Derivative | 15,148 | $0.00 Strike: $219.97 | $0.00 |
DisclosureSEC source: 0001209191-23-033751 · doc4.xml · derivative · entry 3 Majors Cary L · CIK 0001776271 · SVP and President, Healthcare 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,148 Underlying: Ordinary Shares · 15,148 shares Expires 2033-05-31 F3 · derivative.exercise_date: This option becomes exercisable as follows: 3,787 on May 31, 2024; 3,787 on June 2, 2025; 3,787 on June 1, 2026 and 3,787 on June 1, 2027. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
Majors Cary LSVP and President, Healthcare
|
GrantOrdinary Shares | 2,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033751 · doc4.xml · nonDerivative · entry 2 Majors Cary L · CIK 0001776271 · SVP and President, Healthcare 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,393 F2 · balance_after: As of May 31, 2023, 9,860 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 2,367 on June 3, 2024; 1,964 on June 2, 2025; 692 on October 1, 2025; 2,697 on June 1, 2026 and 2,140 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
Majors Cary LSVP and President, Healthcare
|
Tax withholdingOrdinary Shares | 649 | $199.97 | $129,780.53 |
DisclosureSEC source: 0001209191-23-033751 · doc4.xml · nonDerivative · entry 1 Majors Cary L · CIK 0001776271 · SVP and President, Healthcare 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,696 F1 · shares: 649 shares were withheld from the 2,224 restricted shares that vested on May 31, 2023. These 649 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 2,224 ordinary shares were awarded to Mr. Majors on May 31, 2019. These vested shares were valued at the NYSE closing market price on May 31, 2023. F2 · balance_after: As of May 31, 2023, 9,860 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 2,367 on June 3, 2024; 1,964 on June 2, 2025; 692 on October 1, 2025; 2,697 on June 1, 2026 and 2,140 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
TOKICH MICHAEL JSr. Vice Pres., CFO
|
GrantEmployee Stock Option (right to buy) · Derivative | 26,964 | $0.00 Strike: $219.97 | $0.00 |
DisclosureSEC source: 0001209191-23-033757 · doc4.xml · derivative · entry 4 TOKICH MICHAEL J · CIK 0001235611 · Sr. Vice Pres., CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,964 Underlying: Ordinary Shares · 26,964 shares Expires 2033-05-31 F4 · derivative.exercise_date: This option becomes exercisable as follows: 6,741 on May 31, 2024; 6,741 on June 2, 2025; 6,741 on June 1, 2026 and 6,741 on June 1, 2027. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
TOKICH MICHAEL JSr. Vice Pres., CFO
|
GrantOrdinary Shares | 3,879 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033757 · doc4.xml · nonDerivative · entry 2 TOKICH MICHAEL J · CIK 0001235611 · Sr. Vice Pres., CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,464 F2 · balance_after: As of May 31, 2023, 11,455 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 1,293 on May 31, 2024; 2,452 on June 3, 2024; 1,719 on June 3, 2024; 1,128 on June 3, 2024; 432 on October 1, 2024; 1,293 on June 2, 2025; 573 on June 2, 2025; 564 on June 2, 2025; 144 on October 1, 2025; 1,293 on June 1, 2026 and 564 on June 2, 2026. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:30 UTC |
TOKICH MICHAEL JSr. Vice Pres., CFO
|
Tax withholdingOrdinary Shares | 830 | $199.97 | $165,975.10 |
DisclosureSEC source: 0001209191-23-033757 · doc4.xml · nonDerivative · entry 1 TOKICH MICHAEL J · CIK 0001235611 · Sr. Vice Pres., CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,585 F1 · shares: 830 shares were withheld from the 2,780 restricted shares that vested on May 31, 2023. These 830 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These 2,780 ordinary shares were awarded to Mr. Tokich on May 31, 2019. These vested shares were valued at the NYSE closing market price on May 31, 2023. F2 · balance_after: As of May 31, 2023, 11,455 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 1,293 on May 31, 2024; 2,452 on June 3, 2024; 1,719 on June 3, 2024; 1,128 on June 3, 2024; 432 on October 1, 2024; 1,293 on June 2, 2025; 573 on June 2, 2025; 564 on June 2, 2025; 144 on October 1, 2025; 1,293 on June 1, 2026 and 564 on June 2, 2026. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:35 UTC |
Breeden Richard CDirector
|
SaleOrdinary Shares | 12,130 | $208.61 | $2,530,439.30 |
DisclosureSEC source: 0001209191-23-030651 · doc4.xml · nonDerivative · entry 1 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,970 F1 · price: Price reflects a weighted average sale price for multiple transactions ranging from $208.50 to $209.33 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:35 UTC |
FELDMANN CYNTHIA LDirector
|
Exercise / conversionDirector Stock Option (right to buy) · Derivative | 2,058 | $0.00 Strike: $86.23 | $0.00 |
DisclosureSEC source: 0001209191-23-030650 · doc4.xml · derivative · entry 5 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000 Underlying: Ordinary Shares · 4,058 shares Expires 2027-08-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option to purchase 4,058 STERIS ordinary shares, which is fully vested, was received in conjunction with the Redomiciliation of the entity organized under the laws of the U.K. and formerly named STERIS plc ("Old STERIS") in exchange for an option to purchase 4,058 Old STERIS ordinary shares for $86.23 per share, subject to the same terms and conditions as the original Old STERIS stock option, except as otherwise required by law. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:35 UTC |
FELDMANN CYNTHIA LDirector
|
SaleOrdinary Shares | 931 | $209.67 | $195,202.77 |
DisclosureSEC source: 0001209191-23-030650 · doc4.xml · nonDerivative · entry 3 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 705 F2 · price: Price reflects a weighted average sale price for multiple transactions ranging from $209.21 to $209.98 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:35 UTC |
FELDMANN CYNTHIA LDirector
|
SaleOrdinary Shares | 1,127 | $208.55 | $235,035.85 |
DisclosureSEC source: 0001209191-23-030650 · doc4.xml · nonDerivative · entry 2 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,636 F1 · price: Price reflects a weighted average sale price for multiple transactions ranging from $207.97 to $208.77 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:35 UTC |
FELDMANN CYNTHIA LDirector
|
Exercise / conversionOrdinary Shares | 2,058 | $86.23 | $177,461.34 |
DisclosureSEC source: 0001209191-23-030650 · doc4.xml · nonDerivative · entry 1 FELDMANN CYNTHIA L · CIK 0001264554 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,763 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:35 UTC |
Sohi MohsenDirector
|
Exercise / conversionDirector Stock Option (right to buy) · Derivative | 2,069 | $0.00 Strike: $43.92 | $0.00 |
DisclosureSEC source: 0001209191-23-029816 · doc4.xml · derivative · entry 3 Sohi Mohsen · CIK 0001293588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,069 shares Expires 2023-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option to purchase 2,069 STERIS ordinary shares, which is fully vested, was received in conjunction with the Redomiciliation of the entity organized under the laws of the U.K. and formerly named STERIS plc ("Old STERIS") in exchange for an option to purchase 2,069 Old STERIS ordinary shares for $43.92 per share, subject to the same terms and conditions as the original Old STERIS stock option, except as otherwise required by law. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:35 UTC |
Sohi MohsenDirector
|
SaleOrdinary Shares | 2,069 | $212.28 | $439,207.32 |
DisclosureSEC source: 0001209191-23-029816 · doc4.xml · nonDerivative · entry 2 Sohi Mohsen · CIK 0001293588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,361 Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:35 UTC |
Sohi MohsenDirector
|
Exercise / conversionOrdinary Shares | 2,069 | $43.92 | $90,870.48 |
DisclosureSEC source: 0001209191-23-029816 · doc4.xml · nonDerivative · entry 1 Sohi Mohsen · CIK 0001293588 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:35 UTC |
KOSECOFF JACQUELINE BDirector
|
Exercise / conversionDirector Stock Option (right to buy) · Derivative | 4,657 | $0.00 Strike: $43.92 | $0.00 |
DisclosureSEC source: 0001209191-23-029815 · doc4.xml · derivative · entry 4 KOSECOFF JACQUELINE B · CIK 0001209524 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,657 shares Expires 2023-08-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option to purchase 4,657 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 4,657 ordinary shares for $43.92 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:35 UTC |
KOSECOFF JACQUELINE BDirector
|
SaleOrdinary Shares | 4,657 | $212.56 | $989,891.92 |
DisclosureSEC source: 0001209191-23-029815 · doc4.xml · nonDerivative · entry 2 KOSECOFF JACQUELINE B · CIK 0001209524 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Price reflects a weighted average sale price for multiple transactions ranging from $211.80 to $212.72 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:35 UTC |
KOSECOFF JACQUELINE BDirector
|
Exercise / conversionOrdinary Shares | 4,657 | $43.92 | $204,535.44 |
DisclosureSEC source: 0001209191-23-029815 · doc4.xml · nonDerivative · entry 1 KOSECOFF JACQUELINE B · CIK 0001209524 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:35 UTC |
Breeden Richard CDirector
|
SaleOrdinary Shares | 2,737 | $211.00 | $577,507.00 |
DisclosureSEC source: 0001209191-23-029814 · doc4.xml · nonDerivative · entry 1 Breeden Richard C · CIK 0001300622 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,100 F1 · price: Price reflects a weighted average sale price for multiple transactions ranging from $211.00 to $211.02 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.